 The Biomedical Advanced Research and Development Authority BARDA will provide additional funding of up to 2.2 million to support Opiant Pharmaceuticals Incs NASDAQ: OPNT OPNT003, nasal nalmefene, for opioid overdose. The increase in funding is primarily directed toward the costs of Opiants clinical studies to support its submission of OPNT003 to the FDA. 